EPISODE 112
Medtech start-ups need more firms like Aphelion Capital, investors willing to wager as little as $200,000 to get a promising idea going. Managing Partner Ned Scheetz discusses the firm’s origins, name, and plans going forward. This is the first of a two-episode package highlighting a unique joint effort between Aphelion and other co-creators of Cardeation Capital.
Podcast Guest
Ned Scheetz
Managing Partner
Aphelion Capital
Ned has over 20 years of healthcare investing experience. Prior to forming Aphelion, Ned was a partner and managing director with Piper Jaffray Ventures where he focused on investments in emerging medical technology companies. Ned joined Piper from Janus Capital, where he was a senior research analyst covering both healthcare and internet investments. Before beginning his investment career Ned worked in sales and product management for two Fortune 500 firms. Ned is a graduate of Colby College, Duke University's Fuqua School of Business, and was a post-graduate scholar at Oxford University. He has served on numerous private company boards over his career and enjoys working directly with entrepreneurs to help them build their companies in a capital efficient and less dilutive manner.
Meet Our Host
Geoff Pardo
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.